Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2012

View Archived Issues

Buprenorphine/naltrexone combination evaluated in experimental cocaine dependence

Scientists identify new predictors of severe obesity

Nanofiber/VEGF therapy shows potential for use after myocardial infarction

New cause identified of severe X-linked retinitis pigmentosa

CHDI Foundation presents novel HDAC4 inhibitors

Eisai divulges new PGE2/EP4 receptor signaling suppressors

Research at Zafgen yields new candidate obesity drugs

Lykera Biomed reports novel S100-P-directed antibodies

New potential ocular medications designed in Korea

Novel candidate cancer gene therapies developed in U.S.

U.S. university receives grant to set up translational research center

Enrollment complete in two Reolysin studies

Nectid repurposes agomelatine for pain and autism

FDA approves sNDA for Tradjenta

SBIR grant supports CMV antibody program

NIAID supports tuberculosis drug discovery software development

NICE publishes draft guidance on denosumab

Lenvatinib obtains orphan drug status

AbGenomics gains FDA clearance for trial of candidate drug for autoimmune disease

New formulation of palivizumab approved in Japan

FDA clears phase I trial of H5N1 vaccine with GLA vaccine adjuvant

Japanese approval for new dosage of Amaryl

New indication approved for Neoral and Sandimmun in Japan

New phase I study of F-351 begins in China

U.K. alliance set to launch AZD-8931 combination trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...